Could a common blood pressure pill protect the heart after valve replacement?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female aged 40 years or older * Symptomatic severe aortic stenosis (AS) with left ventricular hypertrophy (LVH) who successfully underwent transcatheter aortic valve replacement (TAVR) within the prior 30 days, including native-valve or valve-in-valve TAVR \* Severe AS defined by at least one of the following: aortic valve area ≤1.0 cm²; aortic valve area index ≤0.6 cm²/m²; mean pressure gradient ≥40 mmHg; or maximal aortic valve velocity ≥4.0 m/sec \* LVH defined as left ventricular mass index \>115 g/m² in men or \>95 g/m² in women * Successful TAVR (technical success) meeting all VARC-3 criteria: survival; successful access, delivery, and retrieval of the device; correct positioning of a single prosthetic valve in the proper anatomic location; no additional surgery or procedure related to the device (excluding permanent pacemaker implantation) or to major vascular, access-site, or cardiac structural complications; and intended prosthetic valve performance (mean gradient \<20 mmHg, peak velocity \<3 m/s, Doppler velocity index ≥0.25, and less than moderate aortic regurgitation) * Left ventricular ejection fraction (LVEF) \>40% before TAVR * Provided written informed consent to participate, either voluntarily or through a legal representative Exclusion Criteria: * Hypotension (systolic blood pressure \<90 mmHg) or hemodynamic instability defined as a need for continuous intravenous vasopressor support at screening * Hyperkalemia (serum potassium \>5.5 mmol/L) * Bilateral renal artery stenosis without stent placement * Allergy, hypersensitivity, or prior intolerance to angiotensin receptor blockers * Pregnancy, breastfeeding, or planning to become pregnant * Estimated life expectancy of less than 2 years * Acute coronary syndrome diagnosed within the past 1 year * Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m\^2 by the CKD-EPI equation, or currently undergoing renal replacement therapy * Any other medical condition that, in the investigator's judgment, makes participation in the trial inappropriate